Alex Spira, MD, PhD, discusses a subset analysis of the phase 3 MARIPOSA trial looking at dose interruptions during the course of amivantamab and lazertinib treatment for EGFR-mutant non-small cell lung cancer.
The phase 3 MARIPOSA trial (NCT04487080) investigating the regimen of amivantamab-vmjw (Rybrevant) and lazertinib vs standard-of-care osimertinib (Tagrisso) for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) showed promising results for the superiority of amivantamab/lazertinib over osimertinib.
The combination delivered a longer progression-free survival (PFS) and duration of response (DOR) with a positive overall survival trend. However, questions about the regimen remain. However, a further area of investigation foucuses on the efficacy of the combination regimen if the dose needs to be interrupted.
According to Alex Spira, MD, PhD, FACP, the analysis identified that patients who received dose interruptions within the first 4 months of treatment had a median PFS similar to patients who did not receive dose interruptions.
Here, Spira, thoracic oncologist at Virginia Cancer Specialists, discusses this subset analysis of the MARIPOSA trial.
Transcription:
0:05 | What is found in MARIPOSA that dose interruptions do not affect outcomes that much. If we look at a couple of things, patients who got those interruptions who didn't get those interruptions, we did not see much of a difference in response rates and duration of response; they were pretty much identical. The [adverse] effects were as expected, and the progression-free survival [curves are] basically identical. At 24 months, it was 52% in both arms, with no differences whatsoever.
0:31 | The good news is, if you decide to interrupt [patients] for whatever reason, patients did just as well. The concern is if they have to stop the drug, [they will] lose some of the benefits. But clearly, we are still getting enough dose intensity and patients can still do well, even with occasional dose interruptions. On the study, what we found was physicians could do dose interruptions as they needed. If a patient's having too many [adverse] effects, if they traveled, if a patient required a dose interruption… we should feel very comfortable that it's okay to hold the dose as needed for adverse events, and patients should do just as well.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More